The Foundation supports research that can lead to the creation of better Parkinson's treatments. Here you can search previously awarded grants by keyword, program name, researcher name, institution or organization name and/or year.
FUNDED GRANTS ( 78)
Therapeutic Pipeline Program, 2017
The goal of this project is to find therapeutic drugs for Parkinson's disease (PD) that target alpha-synuclein, a key player in PD. We propose that the negative impact of alpha-synuclein on called vesicles (storage packets) and the block of cell functions, including debris removal (phagocytosis) and nerve signaling, leads to disease progression. We are developing therapeutic comp...
Researchers: Lisa Claire McConlogue, PhD
LRRK2 Biology Consortium, 2017
Although leucine-rich repeat kinase 2 (LRRK2) is the greatest known genetic contributor to Parkinson's disease (PD), little is known about its structure and function. To better understand how this important protein functions in healthy and PD-affected brain cells, we will study the structures of normal and abnormal LRRK2, that is, LRRK2 from cells with genetic changes -- mutations...
Researchers: Susan S. Taylor, PhD
Research Grant, 2017
Promising Outcomes of Original Grant:
Even though most people with Parkinson's disease (PD) do not have a genetic mutation -- a change in their DNA -- that causes the disease, genes can influence the risk of developing PD and its course. Earlier, we sought to identify genes that influence PD progression. By comparing genes of individuals with more and less severe Parkinson's, we identified the gene...
Researchers: Steven Finkbeiner, MD, PhD
PPMI Data Challenge, 2016
Multivariate Prediction of Parkinson's Disease Clinical Progression (2016 PPMI Data Challenge Winner)
Parkinson's disease (PD) is heterogeneous in both clinical representation and prognosis, as indicated by a large diversity of rates of progression in motor as well as non-motor symptoms. It could therefore be helpful to have well-characterized and distinct subtypes of Parkinson's disease slow and fast clinical progression and have early indicators of the clinical progression rate f...
Researchers: Duygu Tosun-Turgut, PhD
Target Validation Pilot Award, 2016
Rare mutations in the PINK1 gene cause familial (inherited) Parkinson's disease (PD). However, it is not known if PINK1 contributes to the development of idiopathic (no known cause) PD. Studies on the function of PINK1 suggest that it plays a role in the breakdown of damaged mitochondria, the energy factories of cells, through a process known as autophagy. Emerging evidence indicat...
Researchers: Garrett Geoffrey Gross, PhD